Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation

Published:2008-01-14 Issue:8 Volume:41 Page:749-751
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Hill Q A,Hill A,Collyns T A,Pearce R M,Cook G

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1705974.pdf

Reference10 articles.

1. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121–3127.

2. Bainton RD, Byrne JL, Davy BJ, Russell NH . CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002; 100: 3843–3844.

3. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G . Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261–267.

4. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404–406.

5. Maury S, Mary JY, Rabian C, Schwarzinger M, Toubert A, Scieux C et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol 2001; 115: 630–641.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Przedtransplantacyjne czynniki ryzyka reaktywacji zakażenia wirusem cytomegalii po przeszczepieniach allogenicznych komórek hematopoetycznych u dzieci i młodych dorosłych;Acta Haematologica Polonica;2013-10

2. Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy;Leukemia & Lymphoma;2013-06-04

3. IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.;Mediterranean Journal of Hematology and Infectious Diseases;2013-04-10

4. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation;Transplant Infectious Disease;2011-05-18

5. Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia;Bone Marrow Transplantation;2010-12-20